Summary of exercised warrants by Board members and senior executives in NXTCL
Stem cell company NextCell Pharma AB ("NXTCL") announces today, that members of the Board Anders Essen-Möller, Edvard Smith, Hans-Peter Ekre, Niclas Löwgren, CEO Mathias Svahn and CFO Leo Groenewegen have exercised all of their respective series TO 1 warrants. In total this means that 173 430 warrants are to be converted, corresponding to a total investment of SEK 867 150. In total, investments from the Board and Management correspond to approximately 6 percent of the total outstanding warrants.Below, each person’s amount of to be exercised series TO 1 warrants is presented: · Mathias